Completion of equity acquisition Harbour BioMed has announced that its wholly owned subsidiary exercised a warrant agreement to acquire common stock in Spruce Biosciences. Consequently, Harbour BioMed now holds approximately 3.8% of Spruce’s total outstanding shares (3.1% on a fully diluted basis). Harbour BioMed’s leadership emphasized that this exercise marks a transition from a traditional licensing relationship to a deeply aligned strategic partnership.
Advancement of novel therapeutic candidates The collaboration is centered on the development of SPR202 (formerly designated as HBM9013), a potent and selective anti-corticotropin-releasing hormone monoclonal antibody. SPR202 is designed to address various endocrine disorders, including congenital adrenal hyperplasia. The candidate was originally incubated by HBM Alpha Therapeutics, a biotechnology unit within the Harbour BioMed ecosystem.
Expansion of global alliance network From late 2025 to early 2026, Harbour BioMed has been actively forming diverse strategic alliances:
-
January 2026: Partnered with Yantai Lannacheng to co-develop next-generation radionuclide drug conjugates.
-
December 2025: Reached an agreement with Bristol Myers Squibb to discover and develop multi-specific antibodies.
-
November 2025: Established a pact with Evinova regarding the integration of Artificial Intelligence (AI).
-
Summer 2025: Announced a partnership with Otsuka Pharmaceutical to advance BCMAxCD3 bispecific T-cell engagers for autoimmune diseases.